Literature DB >> 18509092

CNS aquaporin-4 autoimmunity in children.

A McKeon1, V A Lennon, T Lotze, S Tenenbaum, J M Ness, M Rensel, N L Kuntz, J P Fryer, H Homburger, J Hunter, B G Weinshenker, K Krecke, C F Lucchinetti, S J Pittock.   

Abstract

BACKGROUND: In adult patients, autoantibodies targeting the water channel aquaporin-4 (AQP4) are a biomarker for a spectrum of CNS inflammatory demyelinating disorders with predilection for optic nerves and spinal cord (neuromyelitis optica [NMO]). Here we describe the neurologic, serologic, and radiographic findings associated with CNS AQP4 autoimmunity in childhood.
METHODS: A total of 88 consecutive seropositive children were identified through service evaluation for NMO-IgG. Sera of 75 were tested for coexisting autoantibodies. Clinical information was available for 58.
RESULTS: Forty-two patients (73%) were non-Caucasian, and 20 (34%) had African ethnicity. Median age at symptom onset was 12 years (range 4-18). Fifty-seven (98%) had attacks of either optic neuritis (n = 48; 83%) or transverse myelitis (n = 45; 78%), or both. Twenty-six (45%) had episodic cerebral symptoms (encephalopathy, ophthalmoparesis, ataxia, seizures, intractable vomiting, or hiccups). Thirty-eight (68%) had brain MRI abnormalities, predominantly involving periventricular areas (in descending order of frequency): the medulla, supratentorial and infratentorial white matter, midbrain, cerebellum, thalamus, and hypothalamus. Additional autoantibodies were detected in 57 of 75 patients (76%), and 16 of 38 (42%) had a coexisting autoimmune disorder recorded (systemic lupus erythematosus, Sjögren syndrome, juvenile rheumatoid arthritis, Graves disease). Attacks were recurrent in 54 patients (93%; median follow-up, 12 months). Forty-three of 48 patients (90%) had residual disability: 26 (54%) visual impairment and 21 (44%) motor deficits (median Expanded Disability Status Scale 4.0 at 12 months).
CONCLUSIONS: Aquaporin-4 autoimmunity is a distinctive recurrent and widespread inflammatory CNS disease in children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509092     DOI: 10.1212/01.wnl.0000314832.24682.c6

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  69 in total

1.  Effects of age and sex on aquaporin-4 autoimmunity.

Authors:  Amy M L Quek; Andrew McKeon; Vanda A Lennon; Jayawant N Mandrekar; Raffaele Iorio; Yujuan Jiao; Chiara Costanzi; Brian G Weinshenker; Dean M Wingerchuk; Claudia F Lucchinetti; Elizabeth A Shuster; Sean J Pittock
Journal:  Arch Neurol       Date:  2012-08

Review 2.  Pediatric multiple sclerosis.

Authors:  E Ann Yeh; Tanuja Chitnis; Lauren Krupp; Jayne Ness; Dorothée Chabas; Nancy Kuntz; Emmanuelle Waubant
Journal:  Nat Rev Neurol       Date:  2009-10-13       Impact factor: 42.937

Review 3.  Molecular disruptions of the panglial syncytium block potassium siphoning and axonal saltatory conduction: pertinence to neuromyelitis optica and other demyelinating diseases of the central nervous system.

Authors:  J E Rash
Journal:  Neuroscience       Date:  2009-10-20       Impact factor: 3.590

4.  Neuromyelitis optica - an update: 2007-2009.

Authors:  Anu Jacob
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

5.  Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies.

Authors:  Andrea Bianchi; Emanuele Bartolini; Federico Melani; Renzo Guerrini; Mario Mascalchi
Journal:  J Neurol       Date:  2016-11-14       Impact factor: 4.849

6.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

Review 7.  Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica.

Authors:  Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2016-09       Impact factor: 3.042

8.  Anti-MOG Antibody Seropositive Neuromyelitis Optica: A Rare Pediatric Case.

Authors:  Gonca Koç; Nurettin Bayram; Ahmet Sami Güven; Doğan Bahadır İnan; Ali Kaya
Journal:  Noro Psikiyatr Ars       Date:  2019-02-05       Impact factor: 1.339

Review 9.  What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Authors:  Yeliz Pekcevik; Gunes Orman; In Ho Lee; Maureen A Mealy; Michael Levy; Izlem Izbudak
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

10.  Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case report.

Authors:  Zeljka Petelin Gadze; Sanja Hajnsek; Silvio Basic; Davor Sporis; Goran Pavlisa; Sibila Nankovic
Journal:  BMC Neurol       Date:  2009-10-23       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.